BioMarin Pharmaceutical | BMRN - Interest Expense On Debt


BioMarin Pharmaceutical reported $2.78M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
Incyte USD 582K 10K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025